- InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
- This yield level demonstrates commercial viability; supports advancing to large-scale production for InMed
- two main objectives were laid out: to achieve a commercially viable yield higher than current industry standards and to lower overall manufacturing costs through process optimization
- InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates
- InMed Pharmaceuticals Inc. (IN) is up 10.86 per cent and is trading at C$3.88 at 12:09 pm ET
InMed Pharmaceuticals Inc. (IN) has achieved a level of 2g/L cannabinoid yield with IntegraSyn™.
This milestone signals commercial viability and supports advancement to large-scale production in the coming months.
For its first application using the IntegraSyn™ approach, InMed set two main objectives to enable a cost-effective solution to cannabinoid production: to achieve a commercially viable yield higher than current industry standards and to lower overall manufacturing costs through process optimization.
InMed’s IntegraSyn™ manufacturing approach was able to achieve both objectives.
IntegraSyn™ utilizes an enzymatic biotransformation process as a part of an overall integrated cannabinoid manufacturing approach to overcome certain natural yield limitations of traditional biosynthesis for full cannabinoid assembly.
Having achieved a 2g/L yield level, InMed will now focus on manufacturing scale-up to larger batch sizes while continuing process and enzyme optimization, targeting increased cannabinoid yield and further reducing the overall cost of goods.
In parallel, InMed continues to prepare the manufacturing process to be Good Manufacturing Practice (GMP)-ready for pharmaceutical quality production.
The next stage of large-scale production is to produce a batch with a target output of one kilogram of the selected cannabinoid in 2H2021 via a GMP-ready process.
“As this scale-up progresses, we will also seek to further optimize our manufacturing and purification processes and further enhance the enzyme design,” said Eric Hsu, Senior Vice President, Preclinical R&D.
“I would also like to acknowledge the Almac Group, our collaborator and contract manufacturing partner, for bringing their extensive knowledge and expertise to the program as we reached this important milestone,” added Hsu.
Michael Woudenberg, Vice President of Chemistry, Manufacturing, and Controls, added, “In addition to achieving a commercially viable cannabinoid yield level, we have focused on utilizing cost-competitive starting materials to enable a cost-effective solution to pharmaceutical-grade cannabinoid production with IntegraSyn™.”
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol, in diseases with high unmet medical need.
IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system designed to efficiently and economically produce pharmaceutical-grade, bio-identical cannabinoids.
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
InMed Pharmaceuticals Inc. (IN) is up 10.86 per cent and is trading at C$3.88 at 12:09 pm ET.